{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:15:50Z","timestamp":1793092550795,"version":"4.5.0"},"reference-count":178,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bcp.2026.118381","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T15:11:12Z","timestamp":1787411472000},"page":"118381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"P1","title":["Immunopharmacological reprogramming of innate immune memory in Alzheimer\u2019s disease: From microglial priming to therapeutic resilience"],"prefix":"10.1016","volume":"254","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4747-8549","authenticated-orcid":false,"given":"Ahmed M.","family":"Abdelaziz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem M.","family":"Eladawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.118381_b0005","doi-asserted-by":"crossref","DOI":"10.1590\/1980-5764-dn-2024-0204","article-title":"Advancements in the treatment of Alzheimer\u2019s disease: a comprehensive review","volume":"19","author":"Rajanna","year":"2025","journal-title":"Dement. Neuropsychol."},{"key":"10.1016\/j.bcp.2026.118381_b0010","doi-asserted-by":"crossref","unstructured":"\u201c2024. Alzheimer\u2019s disease facts and figures,\u201d Alzheimer\u2019s Dement. 20(5) 2024 3708\u20133821, doi: 10.1002\/alz.13809.","DOI":"10.1002\/alz.13809"},{"key":"10.1016\/j.bcp.2026.118381_b0015","doi-asserted-by":"crossref","unstructured":"O.V. Forlenza, B.J.A.P. Barbosa, \u201cWhat are the reasons for the repeated failures of clinical trials with anti-amyloid drugs for AD treatment?,\u201d 2025, SciELO Brasil.","DOI":"10.1590\/1980-5764-dn-2025-e001"},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0020","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41392-023-01484-7","article-title":"Amyloid \u03b2-based therapy for Alzheimer\u2019s disease: challenges, successes and future","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"8","key":"10.1016\/j.bcp.2026.118381_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpet.2025.103639","article-title":"Alzheimer disease: amyloid peptide controversies and challenges of anti-A\u03b2 immunotherapy","volume":"392","author":"Almohmadi","year":"2025","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"23","key":"10.1016\/j.bcp.2026.118381_b0030","doi-asserted-by":"crossref","first-page":"7397","DOI":"10.1007\/s00018-021-03986-5","article-title":"Genomics of Alzheimer\u2019s disease implicates the innate and adaptive immune systems","volume":"78","author":"Li","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bcp.2026.118381_b0035","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2020.589196","article-title":"Do Alzheimer\u2019s disease risk gene products actually act in microglia?","volume":"12","author":"Hashioka","year":"2020","journal-title":"Front. Aging Neurosci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0040","first-page":"2","article-title":"Roles of microglia in synaptogenesis, synaptic pruning, and synaptic plasticity in physiological conditions and central nervous system disorders","volume":"24","author":"Xie","year":"2026","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.bcp.2026.118381_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainresbull.2023.110664","article-title":"Emerging non-proinflammatory roles of microglia in healthy and diseased brains","volume":"199","author":"Sun","year":"2023","journal-title":"Brain Res. Bull."},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0050","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41581-022-00633-5","article-title":"Trained immunity\u2014basic concepts and contributions to immunopathology","volume":"19","author":"Ochando","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118381_b0055","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s12016-021-08905-x","article-title":"Immune memory in aging: a wide perspective covering microbiota, brain, metabolism, and epigenetics","volume":"63","author":"Bulut","year":"2022","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0060","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s41232-025-00382-5","article-title":"Innate immune memory in macrophage differentiation and cardiovascular diseases","volume":"45","author":"Nakayama","year":"2025","journal-title":"Inflamm. Regen."},{"key":"10.1016\/j.bcp.2026.118381_b0065","first-page":"745","article-title":"Monocyte\/macrophage-mediated trained immunity in disease prevention and immunotherapy","volume":"59","author":"Zhang","year":"2026","journal-title":"Bioact. Mater."},{"issue":"23","key":"10.1016\/j.bcp.2026.118381_b0070","doi-asserted-by":"crossref","first-page":"11494","DOI":"10.3390\/ijms262311494","article-title":"Microglia in brain aging and age-related diseases: friends or foes?","volume":"26","author":"Ishikawa","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118381_b0075","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2022.878987","article-title":"Microglial priming in infections and its risk to neurodegenerative diseases","volume":"16","author":"Lima","year":"2022","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.bcp.2026.118381_b0080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.neuropharm.2014.10.028","article-title":"Microglial priming and enhanced reactivity to secondary insult in aging, and traumatic CNS injury, and neurodegenerative disease","volume":"96","author":"Norden","year":"2015","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0085","first-page":"Dec","article-title":"Astrocyte priming enhances microglial A\u03b2 clearance and is compromised by APOE4","volume":"16","author":"Lee","year":"2025","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.bcp.2026.118381_b0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/jdad2030029","article-title":"Microglial neuroinflammation in Alzheimer\u2019s disease: mechanisms and therapies","volume":"2","author":"Mcdonald","year":"2025","journal-title":"J. Dement. Alzheimer\u2019s Dis."},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0095","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/imr.13328","article-title":"Discovering adaptive features of innate immune memory","volume":"323","author":"Sadeghi","year":"2024","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.bcp.2026.118381_b0100","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.3389\/fimmu.2019.02806","article-title":"BCG-induced cross-protection and development of trained immunity: implication for vaccine design","volume":"10","author":"Covi\u00e1n","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118381_b0105","doi-asserted-by":"crossref","unstructured":"A. McQuade et al., \u201cTranscriptional regulation of disease-relevant microglial activation programs,\u201d bioRxiv, p. 2025.10.12.681832, Oct. 2025, doi: 10.1101\/2025.10.12.681832.","DOI":"10.1101\/2025.10.12.681832"},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0110","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1038\/s41467-026-68706-8","article-title":"TREM2 expression level is critical for microglial state, metabolic capacity and efficacy of TREM2 agonism","volume":"17","author":"Feiten","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118381_b0115","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2025.1706384","article-title":"Nuclear receptor-driven immunometabolic crosstalk: immune-centric pharmacology targeting the inflamed nexus","volume":"13","author":"Zhang","year":"2026","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bcp.2026.118381_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2025.115537","article-title":"Semaglutide attenuates Alzheimer\u2019s disease model progression by targeting microglial NLRP3 inflammasome-mediated neuroinflammation and ferroptosis","volume":"396","author":"Zheng","year":"2026","journal-title":"Exp. Neurol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0125","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41392-023-01588-0","article-title":"Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets","volume":"8","author":"Gao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0130","article-title":"The immune system in tissue environments regaining homeostasis after injury: is \u2018inflammation\u2019 always inflammation?","volume":"2016","author":"Kulkarni","year":"2016","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.bcp.2026.118381_b0135","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","article-title":"Inflammation as a central mechanism in Alzheimer\u2019s disease","volume":"4","author":"Kinney","year":"2018","journal-title":"Alzheimer\u2019s Dement."},{"key":"10.1016\/j.bcp.2026.118381_b0140","first-page":"1","article-title":"Targeting inflammaging in Alzheimer\u2019s disease: molecular pathways and emerging pharmacotherapies","author":"Alotaibi","year":"2026","journal-title":"Inflammopharmacology"},{"issue":"10","key":"10.1016\/j.bcp.2026.118381_b0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3003426","article-title":"Disease-associated microglia in neurodegenerative diseases: friend or foe?","volume":"23","author":"Cheng","year":"2025","journal-title":"PLoS Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0150","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13024-026-00937-1","article-title":"PU. 1: the conductor of Alzheimer\u2019s symphony","volume":"21","author":"Sun","year":"2026","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.bcp.2026.118381_b0155","first-page":"1","article-title":"Lymphoid gene expression supports neuroprotective microglia function","author":"Ayata","year":"2025","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.bcp.2026.118381_b0160","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1016\/j.neuron.2022.10.020","article-title":"Microglia states and nomenclature: a field at its crossroads","volume":"110","author":"Paolicelli","year":"2022","journal-title":"Neuron"},{"key":"10.1016\/j.bcp.2026.118381_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuron.2026.03.011","article-title":"Deletion of SPI1 in microglia exacerbates amyloid pathology by impairing microglial response in Alzheimer\u2019s disease models","author":"Kim","year":"2026","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.bcp.2026.118381_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00519","article-title":"Senescent brain cell types in Alzheimer\u2019s disease: pathological mechanisms and therapeutic opportunities","volume":"22","author":"Hudson","year":"2025","journal-title":"Neurotherapeutics"},{"issue":"5","key":"10.1016\/j.bcp.2026.118381_b0175","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/febs.16315","article-title":"Untangling senescent and damage\u2010associated microglia in the aging and diseased brain","volume":"290","author":"Ng","year":"2023","journal-title":"FEBS J."},{"key":"10.1016\/j.bcp.2026.118381_b0180","article-title":"Microglial immune regulation by epigenetic reprogramming through histone H3K27 acetylation in neuroinflammation","volume":"14","author":"Huang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118381_b0185","doi-asserted-by":"crossref","DOI":"10.1002\/alz.085990","article-title":"Microglial activation alters chromatin accessibility of AD\u2010associated transcription factors","volume":"20","author":"Chatila","year":"2024","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"2","key":"10.1016\/j.bcp.2026.118381_b0190","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.molmed.2018.11.004","article-title":"Transcriptional and epigenetic regulation of microglia in health and disease","volume":"25","author":"Yeh","year":"2019","journal-title":"Trends Mol. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0195","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00401-026-02990-y","article-title":"Epigenomic subtypes of late-onset Alzheimer\u2019s disease reveal distinct microglial signatures","volume":"151","author":"Laroche","year":"2026","journal-title":"Acta Neuropathol."},{"issue":"20","key":"10.1016\/j.bcp.2026.118381_b0200","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1016\/j.cell.2023.08.037","article-title":"Human microglial state dynamics in Alzheimer\u2019s disease progression","volume":"186","author":"Sun","year":"2023","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0205","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40478-017-0418-8","article-title":"Isolation of primary microglia from the human post-mortem brain: effects of ante- and post-mortem variables","volume":"5","author":"Mizee","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"issue":"9","key":"10.1016\/j.bcp.2026.118381_b0210","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1038\/s41593-025-02020-2","article-title":"Alzheimer\u2019s disease transcriptional landscape in ex vivo human microglia","volume":"28","author":"Kosoy","year":"2025","journal-title":"Nat. Neurosci."},{"issue":"7","key":"10.1016\/j.bcp.2026.118381_b0215","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/s43587-023-00424-y","article-title":"Human microglia show unique transcriptional changes in Alzheimer\u2019s disease","volume":"3","author":"Prater","year":"2023","journal-title":"Nat. Aging"},{"issue":"2","key":"10.1016\/j.bcp.2026.118381_b0220","doi-asserted-by":"crossref","DOI":"10.1002\/alz.71117","article-title":"Generation and characterization of iPSC\u2010derived microglia for in vitro modeling of stimuli\u2010specific neuroimmune responses","volume":"22","author":"Haskell","year":"2026","journal-title":"Alzheimer\u2019s Dement."},{"key":"10.1016\/j.bcp.2026.118381_b0225","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2025.1616470","article-title":"Microglia-containing neural organoids as brain microphysiological systems for long-term culture","volume":"19","author":"Rittenhouse","year":"2025","journal-title":"Front. Cell. Neurosci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0230","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1038\/s41467-025-60099-4","article-title":"The APOE isoforms differentially shape the transcriptomic and epigenomic landscapes of human microglia xenografted into a mouse model of Alzheimer\u2019s disease","volume":"16","author":"Murphy","year":"2025","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.bcp.2026.118381_b0235","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41590-019-0416-z","article-title":"Humanized immune system mouse models: progress, challenges and opportunities","volume":"20","author":"Allen","year":"2019","journal-title":"Nat. Immunol."},{"issue":"18","key":"10.1016\/j.bcp.2026.118381_b0240","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1016\/j.cell.2025.06.031","article-title":"Single-cell multiregion epigenomic rewiring in Alzheimer\u2019s disease progression and cognitive resilience","volume":"188","author":"Liu","year":"2025","journal-title":"Cell"},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2026.118381_b0245","article-title":"Multi\u2010omics insights into Alzheimer\u2019s disease stratification using a microglial polygenic risk score","volume":"21","author":"Kikuchi","year":"2025","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"10.1016\/j.bcp.2026.118381_b0250","doi-asserted-by":"crossref","unstructured":"A. Bergendorf, J.H. Park, B.K. Ball, D.K. Brubaker, \u201cMouse-to-human modeling of microglia single-nuclei transcriptomics identifies immune signaling pathways and potential therapeutic candidates associated with Alzheimer\u2019s disease,\u201d bioRxiv, Feb. 2025, doi: 10.1101\/2025.02.07.637100.","DOI":"10.1101\/2025.02.07.637100"},{"key":"10.1016\/j.bcp.2026.118381_b0255","article-title":"Organoid-microglia system for modeling the immune microenvironment of the brain and retina","volume":"17","author":"Yu","year":"2026","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0260","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/imr.13317","article-title":"Epigenetic control of microglial immune responses","volume":"323","author":"Scholz","year":"2024","journal-title":"Immunol. Rev."},{"issue":"2","key":"10.1016\/j.bcp.2026.118381_b0265","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.molmed.2018.11.004","article-title":"Transcriptional and epigenetic regulation of microglia in health and disease","volume":"25","author":"Yeh","year":"2018","journal-title":"Trends Mol. Med."},{"issue":"6","key":"10.1016\/j.bcp.2026.118381_b0270","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0197-4580(01)00311-6","article-title":"Modeling microglial activation in Alzheimer\u2019s disease with human postmortem microglial cultures","volume":"22","author":"Lue","year":"2001","journal-title":"Neurobiol. Aging"},{"issue":"4","key":"10.1016\/j.bcp.2026.118381_b0275","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/epigenomes5040026","article-title":"The histone h3 k4me3, k27me3, and k27ac genome-wide distributions are differently influenced by sex in brain cortexes and gastrocnemius of the Alzheimer\u2019s disease PSAPP mouse model","volume":"5","author":"Casciaro","year":"2021","journal-title":"Epigenomes"},{"key":"10.1016\/j.bcp.2026.118381_b0280","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1669054","article-title":"DAMP-driven trained immunity: metabolic and epigenetic reprogramming in critical illness and chronic inflammation","volume":"16","author":"Kim","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118381_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2026.157143","article-title":"The IGF-1 senescence switch: a biphasic model for SASP-driven aging and precision senomodulation","volume":"202","author":"Manni","year":"2026","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0290","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s00011-026-02293-8","article-title":"Repurposing niclosamide to mitigate inflammaging: a review of multi-target mechanisms in cellular senescence and age-related decline","volume":"75","author":"Alameen","year":"2026","journal-title":"Inflamm. Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.118381_b0295","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1124\/molpharm.123.000803","article-title":"Pharmacological targeting of senescence with senolytics as a new therapeutic strategy for neurodegeneration","volume":"105","author":"Richardson","year":"2024","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0300","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s11357-024-01308-8","article-title":"Senolytic intervention improves cognition, metabolism, and adiposity in female APPNL\u2212 F\/NL\u2212 F mice","volume":"47","author":"Fang","year":"2025","journal-title":"Geroscience"},{"issue":"03","key":"10.1016\/j.bcp.2026.118381_b0305","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/nep3.56","article-title":"Microglial senescence in neurodegeneration: insights, implications, and therapeutic opportunities","volume":"2","author":"Olajide","year":"2024","journal-title":"Neuroprotection"},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0310","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1038\/s41467-025-60099-4","article-title":"The APOE isoforms differentially shape the transcriptomic and epigenomic landscapes of human microglia xenografted into a mouse model of Alzheimer\u2019s disease","volume":"16","author":"Murphy","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118381_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.tig.2025.12.008","article-title":"Leveraging allelic imbalance in accessible chromatin to prioritize putative causal variants","author":"Morilla","year":"2026","journal-title":"Trends Genet."},{"issue":"7","key":"10.1016\/j.bcp.2026.118381_b0320","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.tig.2025.01.001","article-title":"Chromatin accessibility provides a window into the genetic etiology of human brain disease","volume":"41","author":"Bendl","year":"2025","journal-title":"Trends Genet."},{"key":"10.1016\/j.bcp.2026.118381_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2020.101971","article-title":"Microglial innate memory and epigenetic reprogramming in neurological disorders","volume":"200","author":"Martins-Ferreira","year":"2021","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.bcp.2026.118381_b0330","article-title":"Astrocyte epigenetics as a priority area in neuroscience research","volume":"18","author":"Morales Pantoja","year":"2025","journal-title":"Front. Mol. Neurosci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0335","doi-asserted-by":"crossref","first-page":"7551","DOI":"10.1038\/s41467-025-62995-1","article-title":"Astrocyte priming enhances microglial A\u03b2 clearance and is compromised by APOE4","volume":"16","author":"Lee","year":"2025","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.bcp.2026.118381_b0340","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1038\/s41591-025-03835-z","article-title":"APOE \u03b54 carriers share immune-related proteomic changes across neurodegenerative diseases","volume":"31","author":"Shvetcov","year":"2025","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.bcp.2026.118381_b0345","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bcp.2026.118381_b0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114227","article-title":"Probiotics reverse gut dysbiosis and memory impairment associated with esomeprazole use in chronically stressed rats: a significant neuroprotective role for cholecystokinin","volume":"150","author":"Eladawy","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118381_b0355","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3233\/JAD-210268","article-title":"NLRP3 inflammasome: a starring role in amyloid-\u03b2-and tau-driven pathological events in Alzheimer\u2019s disease","volume":"83","author":"Van Zeller","year":"2021","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.bcp.2026.118381_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114692","article-title":"Alpha-Synuclein drives NURR1 and NLRP3 Inflammasome dysregulation in Parkinson\u2019s disease: from pathogenesis to potential therapeutic strategies","volume":"156","author":"Abdelaziz","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118381_b0365","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s15010-022-01904-w","article-title":"DFV890: a new oral NLRP3 inhibitor\u2014tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function","volume":"51","author":"Madurka","year":"2023","journal-title":"Infection"},{"issue":"5","key":"10.1016\/j.bcp.2026.118381_b0370","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13789","article-title":"First\u2010in\u2010human safety, tolerability, and pharmacokinetic results of DFV890, an oral low\u2010molecular\u2010weight NLRP3 inhibitor","volume":"17","author":"Gatlik","year":"2024","journal-title":"Clin. Transl. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0375","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/1061186X.2025.2542856","article-title":"Ofirnoflast: a first-in-class NEK7-targeted inhibitor of the NLRP3 inflammasome","volume":"34","author":"Mollard","year":"2026","journal-title":"J. Drug Target."},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0380","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3233\/JAD-215370","article-title":"JOTROL, a novel formulation of resveratrol, shows beneficial effects in the 3xTg-AD mouse model","volume":"86","author":"Dennison","year":"2022","journal-title":"J. Alzheimer\u2019s Dis."},{"issue":"Suppl 5","key":"10.1016\/j.bcp.2026.118381_b0385","article-title":"Therapeutic potential of INM\u2010901 in mitigating Alzheimer\u2019s disease pathology: insights from a long\u2010term 5xFAD mouse model study","volume":"21","author":"Somvanshi","year":"2025","journal-title":"Alzheimer\u2019s Dement."},{"issue":"13","key":"10.1016\/j.bcp.2026.118381_b0390","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.3390\/ijms20133328","article-title":"The NLRP3 inflammasome: an overview of mechanisms of activation and regulation","volume":"20","author":"Kelley","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"16","key":"10.1016\/j.bcp.2026.118381_b0395","doi-asserted-by":"crossref","first-page":"8979","DOI":"10.3390\/ijms23168979","article-title":"Targeting NLRP3-mediated neuroinflammation in Alzheimer\u2019s disease treatment","volume":"23","author":"Barczuk","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.bcp.2026.118381_b0400","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.3390\/pharmaceutics13101542","article-title":"Drug penetration into the central nervous system: pharmacokinetic concepts and in vitro model systems","volume":"13","author":"Neumaier","year":"2021","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.bcp.2026.118381_b0405","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3892\/ijmm.2023.5238","article-title":"Inhibitors of the NLRP3 inflammasome pathway as promising therapeutic candidates for inflammatory diseases","volume":"51","author":"Zhang","year":"2023","journal-title":"Int. J. Mol. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.118381_b0410","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/10738584241254118","article-title":"Microglia, Trem2, and neurodegeneration","volume":"31","author":"Shi","year":"2025","journal-title":"Neuroscientist"},{"key":"10.1016\/j.bcp.2026.118381_b0415","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.1022739","article-title":"Metformin: Activation of 5\u2032 AMP-activated protein kinase and its emerging potential beyond anti-hyperglycemic action","volume":"13","author":"Goel","year":"2022","journal-title":"Front. Genet."},{"issue":"5","key":"10.1016\/j.bcp.2026.118381_b0420","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1111\/bcp.12804","article-title":"Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders","volume":"82","author":"Maiese","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0425","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s40364-025-00851-6","article-title":"Immune, blood-brain barrier, and metabolic biomarkers mediate gut-brain axis crosstalk in Alzheimer\u2019s disease","volume":"13","author":"Li","year":"2025","journal-title":"Biomark. Res."},{"issue":"6","key":"10.1016\/j.bcp.2026.118381_b0430","doi-asserted-by":"crossref","DOI":"10.71150\/jm.2503009","article-title":"Targeting innate immune sensors for therapeutic strategies in infectious diseases","volume":"63","author":"Shin","year":"2025","journal-title":"J. Microbiol."},{"issue":"9","key":"10.1016\/j.bcp.2026.118381_b0435","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.cgh.2018.12.032","article-title":"Safety of biologic therapy in older patients with immune-mediated diseases: a systematic review and meta-analysis","volume":"17","author":"Borren","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118381_b0440","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/14728222.2018.1486823","article-title":"Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease?","volume":"22","author":"Deming","year":"2018","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bcp.2026.118381_b0445","article-title":"TREM2 and microglial immunity in Alzheimer\u2019s disease: mechanisms, genetics, and therapeutic opportunities","volume":"17","author":"Wang","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118381_b0450","article-title":"Characterization of the first TREM2 small molecule agonist, VG\u20103927, for clinical development in Alzheimer\u2019s disease","volume":"20","author":"Mirescu","year":"2024","journal-title":"Alzheimer\u2019s Dement."},{"key":"10.1016\/j.bcp.2026.118381_b0455","unstructured":"D. Ollendorf, \u201cStrengthening the FDA\u2019s Accelerated Approval Pathway: Progress and Unfinished Business,\u201d Institute for Clinical and Economic Review, p. 2, 2026."},{"key":"10.1016\/j.bcp.2026.118381_b0460","doi-asserted-by":"crossref","unstructured":"A. J. Hiller, \u201cThe Role of Venture Capital in Drug Discovery,\u201d Trends in CNS Drug Discovery, pp. 411\u2013438, 2025.","DOI":"10.1002\/9783527844678.ch15"},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0465","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s13195-024-01599-1","article-title":"Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer\u2019s disease","volume":"16","author":"Long","year":"2024","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.bcp.2026.118381_b0470","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2025.1576020","article-title":"The potential and challenges of TREM2-targeted therapy in Alzheimer\u2019s disease: insights from the INVOKE-2 study","volume":"17","author":"Ma","year":"2025","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.bcp.2026.118381_b0475","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2024.1420731","article-title":"Decoding sTREM2: its impact on Alzheimer\u2019s disease\u2013a comprehensive review of mechanisms and implications","volume":"16","author":"Lin","year":"2024","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.bcp.2026.118381_b0480","doi-asserted-by":"crossref","unstructured":"Y.Y. Leung, L L.Y. Hui, V.B. Kraus, \u201cColchicine\u2014update on mechanisms of action and therapeutic uses,\u201d in Seminars in arthritis and rheumatism, Elsevier, 2015, pp. 341\u2013350.","DOI":"10.1016\/j.semarthrit.2015.06.013"},{"issue":"2","key":"10.1016\/j.bcp.2026.118381_b0485","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/00002093-200104000-00009","article-title":"Pilot tolerability studies of hydroxychloroquine and colchicine in Alzheimer disease","volume":"15","author":"Aisen","year":"2001","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.bcp.2026.118381_b0490","unstructured":"F.P. Collado, \u201cColchicine as a Repurposed NLRP3 Inflammasome Inhibitor in Amyotrophic Lateral Sclerosis: Mechanistic Rationale, Existing Clinical Evidence, and Proposal for a Precision Biomarker Trial,\u201d 2026."},{"issue":"12","key":"10.1016\/j.bcp.2026.118381_b0495","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0292174","article-title":"The association between BCG treatment in patients with bladder cancer and subsequent risk of developing Alzheimer and other dementia.\u2014a Swedish nationwide cohort study from 1997 to 2019","volume":"18","author":"Wang","year":"2023","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.bcp.2026.118381_b0500","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.3390\/microorganisms10101919","article-title":"BCG vaccine\u2014the road not taken","volume":"10","author":"Dow","year":"2022","journal-title":"Microorganisms"},{"key":"10.1016\/j.bcp.2026.118381_b0505","doi-asserted-by":"crossref","DOI":"10.4137\/GEG.S12270","article-title":"Use of epigenetic drugs in disease: an overview","volume":"6","author":"Heerboth","year":"2014","journal-title":"Genet. Epigenet."},{"issue":"7","key":"10.1016\/j.bcp.2026.118381_b0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104052","article-title":"Restoring the epigenome in Alzheimer\u2019s disease: advancing HDAC inhibitors as therapeutic agents","volume":"29","author":"Pereira","year":"2024","journal-title":"Drug Discov. Today"},{"issue":"8","key":"10.1016\/j.bcp.2026.118381_b0515","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3390\/antiox14081015","article-title":"Epigenetic regulation in ischemic neuroprotection: the dual role of HDACs and hats in neuroinflammation and recovery","volume":"14","author":"Lisek","year":"2025","journal-title":"Antioxidants"},{"key":"10.1016\/j.bcp.2026.118381_b0520","doi-asserted-by":"crossref","first-page":"11015","DOI":"10.2147\/IJN.S549893","article-title":"Nanotechnology for neurodegenerative diseases: recent progress in brain-targeted delivery, stimuli-responsive platforms, and organelle-specific therapeutics","author":"Gao","year":"2025","journal-title":"Int. J. Nanomed."},{"issue":"5","key":"10.1016\/j.bcp.2026.118381_b0525","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nbt.3199","article-title":"Epigenome editing by a CRISPR\/Cas9-based acetyltransferase activates genes from promoters and enhancers","volume":"33","author":"Hilton","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bcp.2026.118381_b0530","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ymeth.2019.05.003","article-title":"CRISPR\/Cas9-based epigenome editing: an overview of dCas9-based tools with special emphasis on off-target activity","volume":"164\u2013165","author":"Tadi\u0107","year":"2019","journal-title":"Methods"},{"key":"10.1016\/j.bcp.2026.118381_b0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2020.113506","article-title":"TREM2 overexpression rescues cognitive deficits in APP\/PS1 transgenic mice by reducing neuroinflammation via the JAK\/STAT\/SOCS signaling pathway","volume":"336","author":"Ruganzu","year":"2021","journal-title":"Exp. Neurol."},{"issue":"9","key":"10.1016\/j.bcp.2026.118381_b0540","doi-asserted-by":"crossref","first-page":"10425","DOI":"10.1096\/fj.201900527R","article-title":"Microglial Trem2 induces synaptic impairment at early stage and prevents amyloidosis at late stage in APP\/PS1 mice","volume":"33","author":"Sheng","year":"2019","journal-title":"FASEB J."},{"issue":"8","key":"10.1016\/j.bcp.2026.118381_b0545","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41592-021-01207-2","article-title":"Transgenic mice for in vivo epigenome editing with CRISPR-based systems","volume":"18","author":"Gemberling","year":"2021","journal-title":"Nat. Methods"},{"key":"10.1016\/j.bcp.2026.118381_b0550","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118381_b0555","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2024.1317125","article-title":"Established and emerging techniques for the study of microglia: visualization, depletion, and fate mapping","volume":"18","author":"Bobotis","year":"2024","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.bcp.2026.118381_b0560","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.bbi.2025.05.027","article-title":"HDAC inhibitors engage MITF and the disease-associated microglia signature to enhance amyloid \u03b2 uptake","volume":"129","author":"Haage","year":"2025","journal-title":"Brain Behav. Immun."},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0565","doi-asserted-by":"crossref","first-page":"7948","DOI":"10.1038\/s41467-025-63167-x","article-title":"Programmable epigenome editing by transient delivery of CRISPR epigenome editor ribonucleoproteins","volume":"16","author":"Xu","year":"2025","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.bcp.2026.118381_b0570","first-page":"1155","article-title":"Glycometabolic reprogramming of microglia in neurodegenerative diseases: insights from neuroinflammation","volume":"15","author":"Huang","year":"2024","journal-title":"Aging Dis."},{"key":"10.1016\/j.bcp.2026.118381_b0575","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cotox.2018.05.002","article-title":"mTOR\/AMPK signaling in the brain: cell metabolism, proteostasis and survival","volume":"8","author":"Garza-Lomb\u00f3","year":"2018","journal-title":"Curr. Opin Toxicol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0580","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13075-025-03647-z","article-title":"The Glycolysis-HIF-1\u03b1 axis induces IL-1\u03b2 of macrophages in rheumatoid arthritis","volume":"27","author":"Jia","year":"2025","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bcp.2026.118381_b0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2023.105614","article-title":"The immunometabolic reprogramming of microglia in Alzheimer\u02bcs disease","volume":"171","author":"Chen","year":"2023","journal-title":"Neurochem. Int."},{"issue":"6","key":"10.1016\/j.bcp.2026.118381_b0590","first-page":"3361","article-title":"Immunometabolism in brain aging and neurodegeneration: bridging metabolic pathways and immune responses","volume":"16","author":"Rahimpour","year":"2024","journal-title":"Aging Dis."},{"issue":"2","key":"10.1016\/j.bcp.2026.118381_b0595","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3390\/pathogens14020196","article-title":"Beyond tuberculosis: the surprising immunological benefits of the Bacillus Calmette\u2013Gu\u00e9rin (BCG) vaccine in infectious, auto-immune, and inflammatory diseases","volume":"14","author":"Jurczak","year":"2025","journal-title":"Pathogens"},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0600","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s43046-026-00340-3","article-title":"Comprehensive evaluation of Bacillus Calmette\u2013Gu\u00e9rin therapy in non-muscle invasive bladder cancer Egyptian patients: a retrospective cohort study","volume":"38","author":"Karkeet","year":"2026","journal-title":"J. Egypt. Natl. Cancer Inst."},{"key":"10.1016\/j.bcp.2026.118381_b0605","article-title":"Reversing inflammatory diseases via trained immunity: mechanisms, challenges, and prospects","volume":"16","author":"Xu","year":"2025","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.bcp.2026.118381_b0610","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afaf331","article-title":"Association between vaccinations and risk of dementia: a systematic review and meta-analysis","volume":"54","author":"Maggi","year":"2025","journal-title":"Age Ageing"},{"issue":"5","key":"10.1016\/j.bcp.2026.118381_b0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e27425","article-title":"Protective role of Bacillus Calmette\u2013Gu\u00e9rin vaccine in Alzheimer\u2019s disease progression: a systematic review and meta-analysis","volume":"10","author":"Umar","year":"2024","journal-title":"Heliyon"},{"issue":"9","key":"10.1016\/j.bcp.2026.118381_b0620","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/j.immuni.2024.07.021","article-title":"BCG vaccination alters the epigenetic landscape of progenitor cells in human bone marrow to influence innate immune responses","volume":"57","author":"Sun","year":"2024","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.bcp.2026.118381_b0625","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3390\/vaccines14050412","article-title":"Bacillus Calmette\u2013Gu\u00e9rin (BCG) vaccination and the immune\u2013brain axis: implications for neuroprotection and neurodegenerative disease","volume":"14","author":"Druszczynska","year":"2026","journal-title":"Vaccines"},{"key":"10.1016\/j.bcp.2026.118381_b0630","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neurobiolaging.2021.01.001","article-title":"Bacille Calmette-Gu\u00e9rin attenuates vascular amyloid pathology and maximizes synaptic preservation in APP\/PS1 mice following active amyloid-\u03b2 immunotherapy","volume":"101","author":"Zuo","year":"2021","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bcp.2026.118381_b0635","doi-asserted-by":"crossref","unstructured":"J. Liu et al., \u201cEpigenetic adaptation drives monocyte differentiation into microglia-like cells upon engraftment into the central nervous system,\u201d bioRxiv, p. 2024.09.09.612126, Jul. 2025, doi: 10.1101\/2024.09.09.612126.","DOI":"10.1101\/2024.09.09.612126"},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0640","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12967-023-03944-8","article-title":"BCG-induced trained immunity: history, mechanisms and potential applications","volume":"21","author":"Chen","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bcp.2026.118381_b0645","article-title":"BCG and beyond: unlocking new frontiers in TB vaccine development","volume":"16","author":"Shaji","year":"2025","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.bcp.2026.118381_b0650","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.7150\/ijbs.115515","article-title":"Recent advances of trained immunity in macrophages","volume":"21","author":"Li","year":"2025","journal-title":"Int. J. Biol. Sci."},{"issue":"2","key":"10.1016\/j.bcp.2026.118381_b0655","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.chom.2020.05.014","article-title":"BCG vaccination in humans elicits trained immunity via the hematopoietic progenitor compartment","volume":"28","author":"Cirovic","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.bcp.2026.118381_b0660","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.106339","article-title":"Bioengineering approaches to trained immunity: physiologic targets and therapeutic strategies","volume":"14","author":"Knight","year":"2025","journal-title":"eLife"},{"key":"10.1016\/j.bcp.2026.118381_b0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2024.117126","article-title":"Impact of different gastric acid suppressants on chronic unpredictable mild stress-induced cognitive impairment in rats: a possible involvement of gut dysbiosis","volume":"492","author":"Eladawy","year":"2024","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118381_b0670","first-page":"1","article-title":"The gut-brain axis: a critical link between type 2 diabetes and Parkinson\u2019s disease","volume":"2026","author":"Almohmadi","year":"2026","journal-title":"Probiotics Antimicrob. Proteins"},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0675","doi-asserted-by":"crossref","DOI":"10.1136\/gpsych-2023-101374","article-title":"Gut microbiota\u2010derived short\u2010chain fatty acids and depression: deep insight into biological mechanisms and potential applications","volume":"37","author":"Cheng","year":"2024","journal-title":"Gen. Psychiatr."},{"issue":"13","key":"10.1016\/j.bcp.2026.118381_b0680","doi-asserted-by":"crossref","DOI":"10.1172\/JCI194443","article-title":"Thwarting amyloidosis: IL-17 as a disease modifier along the gut\/brain axis","volume":"135","author":"Self","year":"2025","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0685","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s43556-025-00400-5","article-title":"Pro-resolving lipid mediators in diseases: exploring the molecular basis and clinical implication","volume":"7","author":"Li","year":"2026","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.bcp.2026.118381_b0690","article-title":"Lipoxins in the nervous system: brighter prospects for neuroprotection","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0695","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41401-022-00944-0","article-title":"Formyl peptide receptor 2 as a potential therapeutic target for inflammatory bowel disease","volume":"44","author":"Yang","year":"2022","journal-title":"Acta Pharmacologica Sinica"},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0700","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1021\/acsptsci.9b00075","article-title":"New advances in targeting the resolution of inflammation: implications for specialized pro-resolving mediator GPCR drug discovery","volume":"3","author":"Park","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.bcp.2026.118381_b0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2022.101605","article-title":"Specialized pro-resolving mediators as modulators of immune responses","volume":"59","author":"Julliard","year":"2022","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.bcp.2026.118381_b0710","doi-asserted-by":"crossref","DOI":"10.2174\/0109298673469433260519072139","article-title":"Challenges and prospects for clinical application of specialized pro-resolving lipid mediators and their synthetic analogues in atherosclerosis","volume":"33","author":"Kotlyarov","year":"2026","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118381_b0715","article-title":"Reprogramming microglia in sepsis-associated encephalopathy: from pathological dysfunction to therapeutic restoration","volume":"17","author":"He","year":"2026","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0720","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13024-025-00825-0","article-title":"Decoding microglial immunometabolism: a new frontier in Alzheimer\u2019s disease research","volume":"20","author":"Jung","year":"2025","journal-title":"Mol. Neurodegeneration"},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0725","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12974-024-03015-9","article-title":"Taming microglia: the promise of engineered microglia in treating neurological diseases","volume":"21","author":"Luo","year":"2024","journal-title":"J. Neuroinflammation"},{"issue":"7","key":"10.1016\/j.bcp.2026.118381_b0730","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2530977123","article-title":"Engineering chimeric antigen receptor CD4 T cells for Alzheimer\u2019s disease","volume":"123","author":"Boskovic","year":"2026","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.bcp.2026.118381_b0735","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41434-025-00534-9","article-title":"Expression of anti-amyloid CARs in microglia promotes efficient and selective phagocytosis of A\u03b21\u201242","volume":"32","author":"Heiss","year":"2025","journal-title":"Gene Ther."},{"key":"10.1016\/j.bcp.2026.118381_b0740","doi-asserted-by":"crossref","DOI":"10.1016\/j.tips.2026.02.009","article-title":"Programmable CAR immunotherapies for neurodegenerative proteinopathies","author":"Pesce","year":"2026","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2026.118381_b0745","doi-asserted-by":"crossref","DOI":"10.3724\/abbs.2026017","article-title":"CAR-macrophages: a new chapter in cancer immunotherapy","author":"Tang","year":"2026","journal-title":"Acta Biochim. Biophys. Sin. (Shanghai)"},{"issue":"2","key":"10.1016\/j.bcp.2026.118381_b0750","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/CM9.0000000000002513","article-title":"Generating universal chimeric antigen receptor expressing cell products from induced pluripotent stem cells: beyond the autologous CAR-T cells","volume":"136","author":"Deng","year":"2023","journal-title":"Chin. Med. J. (Engl.)"},{"issue":"3","key":"10.1016\/j.bcp.2026.118381_b0755","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3233\/JAD-190817","article-title":"Transplantation of mesenchymal stem cells improves amyloid-\u03b2 pathology by modifying microglial function and suppressing oxidative stress","volume":"72","author":"Yokokawa","year":"2019","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.bcp.2026.118381_b0760","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1675807","article-title":"Beyond CAR-T Cells: exploring CAR-NK, CAR-M, and CAR-\u03b3\u03b4 T strategies in solid tumor immunotherapy","volume":"16","author":"Hou","year":"2025","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118381_b0765","doi-asserted-by":"crossref","first-page":"465","DOI":"10.17305\/bb.2023.9675","article-title":"CAR-macrophage versus CAR-T for solid tumors: the race between a rising star and a superstar","volume":"24","author":"Chen","year":"2024","journal-title":"Biomol. Biomed."},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0770","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0775","doi-asserted-by":"crossref","DOI":"10.1007\/s12035-025-05563-4","article-title":"Advances in intranasal delivery of exosomes for central nervous system disorders","volume":"63","author":"Arjmand","year":"2025","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bcp.2026.118381_b0780","article-title":"CAR-exosomes derived from immune cells: an emerging nanoscale vanguard in overcoming tumor immunotherapy hurdles","volume":"16","author":"Zhao","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118381_b0785","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112740","article-title":"The chemically stable analogue of resolvin D1 ameliorates experimental autoimmune encephalomyelitis by mediating the resolution of inflammation","volume":"140","author":"Zhang","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118381_b0790","doi-asserted-by":"crossref","first-page":"834","DOI":"10.3390\/diagnostics15070834","article-title":"Serum Maresin-1 and Resolvin-D1 levels as non-invasive biomarkers for monitoring disease activity in ulcerative colitis","volume":"15","author":"Demirci","year":"2025","journal-title":"Diagnostics"},{"key":"10.1016\/j.bcp.2026.118381_b0795","doi-asserted-by":"crossref","DOI":"10.1186\/s12987-026-00760-2","article-title":"Bridging the blood-brain barrier: strategies to improve delivery of biologics to tumors in the brain","author":"Gampa","year":"2026","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.bcp.2026.118381_b0800","doi-asserted-by":"crossref","DOI":"10.2147\/IJN.S588836","article-title":"Intranasal nano-delivery systems: emerging strategies for central nervous system disease therapeutics","author":"Gao","year":"2026","journal-title":"Int. J. Nanomed."},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2024.100013","article-title":"Microglial activation states and their implications for Alzheimer\u2019s Disease","volume":"12","author":"Valiukas","year":"2025","journal-title":"J. Prev Alzheimers Dis."},{"key":"10.1016\/j.bcp.2026.118381_b0810","doi-asserted-by":"crossref","first-page":"Dec","DOI":"10.1016\/j.bioorg.2024.107912","article-title":"Therapeutic role of NLRP3 inflammasome inhibitors against Alzheimer\u2019s disease","volume":"153","author":"Tantra","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bcp.2026.118381_b0815","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2024.109941","article-title":"NLRP3 inflammasome signalling in Alzheimer\u2019s disease","volume":"252","author":"McManus","year":"2024","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.bcp.2026.118381_b0820","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41591-026-04273-1","article-title":"The TREM2 agonistic antibody AL002 in early Alzheimer\u2019s disease: a phase 2 randomized trial","volume":"32","author":"Mummery","year":"2026","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0825","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-025-00824-1","article-title":"The role of n-3-derived specialised pro-resolving mediators (SPMs) in microglial mitochondrial respiration and inflammation resolution in Alzheimer\u2019s disease","volume":"20","author":"Slayo","year":"2025","journal-title":"Mol. Neurodegener."},{"issue":"17","key":"10.1016\/j.bcp.2026.118381_b0830","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.15252\/embj.201797397","article-title":"APP mouse models for Alzheimer\u2019s disease preclinical studies","volume":"36","author":"Sasaguri","year":"2017","journal-title":"EMBO J."},{"issue":"12","key":"10.1016\/j.bcp.2026.118381_b0835","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.molmed.2024.10.010","article-title":"Advancements and challenges in mouse models of Alzheimer\u2019s disease","volume":"30","author":"Qian","year":"2024","journal-title":"Trends Mol. Med."},{"issue":"4","key":"10.1016\/j.bcp.2026.118381_b0840","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3390\/cimb48040426","article-title":"Microglial innate immune memory: implications and research advances in central nervous system disorders","volume":"48","author":"Song","year":"2026","journal-title":"Curr. Issues Mol. Biol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118381_b0845","doi-asserted-by":"crossref","first-page":"110","DOI":"10.14283\/jpad.2018.16","article-title":"Minimizing the sample sizes of clinical trials on preclinical and early symptomatic stage of Alzheimer disease","volume":"5","author":"Luo","year":"2018","journal-title":"J. Prev Alzheimers Dis."},{"issue":"6","key":"10.1016\/j.bcp.2026.118381_b0850","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s43441-024-00698-3","article-title":"Latest developments in \u2018adaptive enrichment\u2019 clinical trial designs in oncology","volume":"58","author":"Tu","year":"2024","journal-title":"Ther. Innov. Regul. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0855","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13195-022-01015-6","article-title":"The role of basket trials in drug development for neurodegenerative disorders","volume":"14","author":"Cummings","year":"2022","journal-title":"Alzheimers Res. Ther."},{"issue":"6","key":"10.1016\/j.bcp.2026.118381_b0860","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1038\/s41380-025-02939-9","article-title":"Neuroinflammatory fluid biomarkers in patients with Alzheimer\u2019s disease: a systematic literature review","volume":"30","author":"Heneka","year":"2025","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2026.118381_b0865","doi-asserted-by":"crossref","unstructured":"E. Ghanbarian et al., \u201cCSF inflammatory cytokines as prognostic indicators for cognitive decline across Alzheimer\u2019s disease spectrum,\u201d medRxiv, 2024.","DOI":"10.1101\/2024.11.13.24317270"},{"issue":"1","key":"10.1016\/j.bcp.2026.118381_b0870","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12974-022-02463-5","article-title":"Epigenetic regulation of innate immune memory in microglia","volume":"19","author":"Zhang","year":"2022","journal-title":"J. Neuroinflammation"},{"issue":"6","key":"10.1016\/j.bcp.2026.118381_b0875","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1161\/01.STR.6.6.707","article-title":"Cerebrospinal fluid and arterial lactate, pyruvate and acid-base balance in patients with intracranial hemorrhages","volume":"6","author":"Fujishima","year":"1975","journal-title":"Stroke"},{"issue":"9","key":"10.1016\/j.bcp.2026.118381_b0880","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.3390\/nu15092211","article-title":"Short-chain fatty-acid-producing bacteria: key components of the human gut microbiota","volume":"15","author":"Fusco","year":"2023","journal-title":"Nutrients"},{"issue":"13","key":"10.1016\/j.bcp.2026.118381_b0885","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.3390\/ijms20133161","article-title":"Recent developments in TSPO PET imaging as a biomarker of neuroinflammation in neurodegenerative disorders","volume":"20","author":"Werry","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.bcp.2026.118381_b0890","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1158\/1078-0432.CCR-08-2788","article-title":"Epigenetic modifiers: basic understanding and clinical development","volume":"15","author":"Piekarz","year":"2009","journal-title":"Clin. Cancer Res."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226007203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226007203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:22:07Z","timestamp":1787718127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226007203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":178,"alternative-id":["S0006295226007203"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118381","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunopharmacological reprogramming of innate immune memory in Alzheimer\u2019s disease: From microglial priming to therapeutic resilience","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118381","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118381"}}